{"filing":{"accession_number":"0001731122-26-001271","cik":"0001553788","ticker":"SBEVW","company_name":"Endovia Health Sciences, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"e7964_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226001271/e7964_8k.htm"},"events":[{"id":34310,"run_id":31577,"accession_number":"0001731122-26-001271","anchor_item_number":"7.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses the closing of $500,000 in \"secured convertible debt funding\" from C/M Capital Master Fund, LP, representing the first tranche of a $1 million investment commitment. This is a direct creation of a new financial obligation through convertible debt issuance, which falls squarely within the debt_issuance category. The materiality is clear given the capital raise supports the company's CannEpil® development program and regulatory advancement strategy.","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37999,"accession_number":"0001731122-26-001271","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the closing of $500,000 in \"secured convertible debt funding\" from C/M Capital Master Fund, LP, representing the first tranche of a $1 million investment commitment. This is a direct creation of a new financial obligation through convertible debt issuance, which falls squarely within the debt_issuance category. The materiality is clear given the capital raise supports the company's CannEpil® development program and regulatory advancement strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:11:54.626162+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37999,"accession_number":"0001731122-26-001271","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the closing of $500,000 in \"secured convertible debt funding\" from C/M Capital Master Fund, LP, representing the first tranche of a $1 million investment commitment. This is a direct creation of a new financial obligation through convertible debt issuance, which falls squarely within the debt_issuance category. The materiality is clear given the capital raise supports the company's CannEpil® development program and regulatory advancement strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:11:54.626162+00:00","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-09-22"}]}